T-Cell Engager Therapeutics Summit Europe

T-Cell Engager Therapeutics Summit Europe is organized by Hanson Wade and will be held from Dec 09 - 11, 2025 at Park Plaza Victoria London, London, England, United Kingdom.

Description:
Fresh from the success of our Boston meeting, we're bringing the momentum to Europe for the very first time. This dedicated forum will unite leading minds in preclinical research, translational science, immunology, and oncology drug development to unlock the full potential of T-cell engagers and accelerate their path to the clinic.

The field is moving at unprecedented speed: with 8 TCE approvals, the space is attracting record investment and partnerships – AbbVie's $2.1B deal with Xilio and Sanofi's €15M partnership with Innate Pharma being just two recent examples. As pharma and biotech double down on next-generation immunotherapies, the race is on to push the boundaries of what TCEs can achieve.

But challenges remain. Target selection, bioavailability, immunogenicity, and translational hurdles continue to limit therapeutic windows, while the expansion into autoimmune disease opens new complexities and opportunities. This summit will bring together the leaders driving innovation to overcome these barriers and redefine the future of TCEs.

Speakers: Petra Lutterbuese, Principal Scientist, Amgen, Christopher Lloyd, Director, AstraZeneca, Nicolas Sabarth, Head, Research Laboratory Biotherapeutics Discovery and Cancer Immunology, Boehringer Ingelheim, Kara Olson, Fellow Scientist, Regeneron, Sara Colombetti, Head, Global Department, Roche, Simon Plyte, Chief Scientific Officer, BIOMUNEX, Steven Quayle, Senior Vice President and Head, Research and Translational Medicine Cue, Biopharma, Jeff Jones, Chief Medical Officer Cullinan, Therapeutics, Alfred Lim, Director, Lab Research, Etcembly, Sarah Missel, Vice President, Bispecifics Portfolio Development, Immatics, Kate Atkin, Associate Director, Immunocore, Kate Rochlin, Chief Operating Officer, IN8Bio, Sara Majocchi, Project Director, Light Chain Biosciences, Marcela Guzman, Senior Director and Head, In Vitro Pharmacology, Molecular Partners, David Granger, Vice President, Research and Development, NovalGen, Thomas Andresen, Chief Executive Officer, T-Cypher Bio, Uli Bialucha, Chief Scientific Officer, Xilio Therapeutics, Nina Weisser, Director, Multispecific Antibody Therapeutics, Zymeworks, Ken Howard, Associate Professor, Aarhus University, Matthias Peipp, Professor, University of Kiel